Follow this blog:
RSS

‘Dark matter’ DNA breakthrough could boost drug research

By | September 12, 2012, 3:00 AM PDT

When we think of DNA, we think of our genes.

But new research shows we should also look at the 99% of our DNA that isn’t genes. Once called “junk DNA” (which was a terrible name considering that we had not proved it didn’t have a purpose; we just didn’t know what the purpose was), this so-called dark matter DNA turns out to be hugely important.

A federal undertaking involving 440 scientists from 32 laboratories from around the world determined that it plays ”a critical role in determining how cells, organs and other tissues behave,” The New York Times reports. The analysis of this gargantuan project required the equivalent of more than three centuries of computer time.

The results, published last week in almost 40 articles in publications such as Nature, Genome Research and Genome Biology, show that much of this dark matter DNA contains gene switches that:

  • control which genes are active in a cell and when
  • determine whether a cell becomes a neuron or a liver cell
  • affect a whole host of diseases such as multiple sclerosis, lupus, rheumatoid arthritis, Crohn’s disease, celiac disease and more

“Most of the changes that affect disease don’t lie in the genes themselves; they lie in the switches,” Michael Snyder, a Stanford University researcher for the project, called Encode, for Encyclopedia of DNA Elements, told The Times.

Applications

The results of this study will greatly impact our health and business, since these gene switches appear to influence so many diseases.

The news could drive drug research and help us understand the environmental influence of disease risk and even explain why one twin gets a disease while the other doesn’t.

“These papers are very significant,” said Dr. Mark A. Rubin, a prostate cancer genomics researcher at Weill Cornell Medical College. Dr. Rubin, who was not part of the Encode project, added, “They will definitely have an impact on our medical research on cancer.”

Start your week smarter with our weekly e-mail newsletter. It's your cheat sheet for good ideas. Get it.

Laura Shin

About Laura Shin

Laura Shin is a contributing editor for SmartPlanet.

Laura Shin

Laura Shin

Contributing Editor

Laura Shin has been published in The New York Times, The Wall Street Journal and The Los Angeles Times, and is currently a contributor at Forbes. Previously, she worked at Newsweek, the New York Times, Wall Street Journal and LearnVest. She holds degrees from Stanford University and Columbia University's Graduate School of Journalism.

Follow her on Twitter.

Laura Shin

Laura Shin

In the unlikely event that Laura has a professional or financial relationship with a company she writes about, it will be prominently disclosed.

She writes for SmartPlanet and is not an employee of CBS.

If you liked this, don't miss...
2
Comments

Join the conversation!

Follow via:
RSS
+1 Vote
+ -
Three centuries?
Whoever came up with the phrase "the equivalent of more than three centuries of computer time" needs to qualify that statement. What might take three years to process on a computer like the one on which I am typing this might only take three days on a super computer. I wonder how they define a "year of computer time".
Posted by omb00900@...
12th Sep
0 Votes
+ -
some information for lupus
This is good news especially when I have a family member that suffers from lupus. However according to my brother, it can also be controlled by nutrition like consumption of grapeseed extract. This can be an option to consider for now since it is a natural source.
Posted by Wilson Yeo
12th Sep
Join the conversation
Formatting +
BB Codes - Note: HTML is not supported in forums
  • [b] Bold [/b]
  • [i] Italic [/i]
  • [u] Underline [/u]
  • [s] Strikethrough [/s]
  • [q] "Quote" [/q]
  • [ol][*] 1. Ordered List [/ol]
  • [ul][*] · Unordered List [/ul]
  • [pre] Preformat [/pre]
  • [quote] "Blockquote" [/quote]

Join the SmartPlanet community and join the conversation! Signing up is fast and free. Don't wait -- we want to hear your opinion!